LAROTRECTINIB for Soft tissue sarcoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 18 adverse event reports in the FDA FAERS database where LAROTRECTINIB was used for Soft tissue sarcoma.
Most Reported Side Effects for LAROTRECTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Fatigue | 56 | 7.0% | 5 | 7 |
| Drug ineffective | 52 | 6.5% | 11 | 3 |
| Dizziness | 50 | 6.3% | 1 | 7 |
| Death | 48 | 6.0% | 48 | 2 |
| Pain | 42 | 5.3% | 4 | 9 |
| Neuropathy peripheral | 39 | 4.9% | 2 | 1 |
| Nausea | 32 | 4.0% | 1 | 5 |
| Off label use | 31 | 3.9% | 7 | 4 |
| Disease progression | 27 | 3.4% | 3 | 1 |
| Malignant neoplasm progression | 23 | 2.9% | 6 | 1 |
| Myalgia | 23 | 2.9% | 0 | 1 |
| Vomiting | 23 | 2.9% | 6 | 14 |
| Drug resistance | 19 | 2.4% | 3 | 1 |
| Anaemia | 18 | 2.3% | 3 | 7 |
| Diarrhoea | 18 | 2.3% | 3 | 9 |
Other Indications for LAROTRECTINIB
Thyroid cancer (43)
Neoplasm (31)
Neoplasm malignant (28)
Ntrk gene fusion cancer (26)
Ntrk gene fusion positive (25)
Sarcoma (25)
Lung neoplasm malignant (24)
Glioblastoma (21)
Congenital fibrosarcoma (18)
Pancreatic carcinoma (18)
Other Drugs Used for Soft tissue sarcoma
PAZOPANIB (1,400)
DOXORUBICIN (302)
TAZEMETOSTAT HYDROBROMIDE (298)
IFOSFAMIDE (237)
CABOZANTINIB S-MALATE (192)
TRABECTEDIN (183)
NIVOLUMAB (156)
OLARATUMAB (156)
IMATINIB (124)
SUNITINIB MALATE (123)